Cleveland Clinic | Strategic Alliance Partners
Cleveland Clinic Cancer Institute provides complete cancer care enhanced by innovative basic, clinical and translational research. It offers the most effective techniques to achieve long-term survival and improve patients’ quality of life. Cleveland Clinic Cancer Institute’s more than 800 physicians, researchers, nurses and technicians care for thousands of patients each year and provide access to a wide range of clinical trials. Cleveland Clinic Cancer Institute has a global presence, uniting clinicians based in our Cancer Institute, Cleveland Clinic’s other patient-centered institutes, our regional hospitals and health centers, and our operations in Florida, London and Abu Dhabi. Cleveland Clinic is a nonprofit, multi-specialty academic medical center with more than 5,000 staff physicians and researchers who integrate outpatient and hospital care with research and education for better patient outcomes and experience. Cleveland Clinic is a trusted healthcare leader. We’re recognized in the U.S. and throughout the world for our expertise and care.
Be sure to tune into our Cancer Advances podcast where we explore the latest innovative research and clinical advances in the field of oncology. Listen now!
Latest from Cleveland Clinic
Holistic and Multidisciplinary Approaches to Multiple Myeloma Management
Beth M. Faiman, PhD, CNP, Cleveland Clinic
Closing out their program on multiple myeloma, expert panelists consider the role of holistic and multidisciplinary care when managing patients within the current paradigm.
Impact of Clinical Trials on the Management of Multiple Myeloma
Beth M. Faiman, PhD, CNP, Cleveland Clinic
Continuing its discussion on clinical trials in multiple myeloma, the panel emphasizes the impact that data may have on the real-world treatment landscape.
Importance of Clinical Trial Enrollment in Multiple Myeloma
Beth M. Faiman, PhD, CNP, Cleveland Clinic
Key opinion leaders in multiple myeloma management elucidate the value of clinical trials and share enthusiasm for improving enrollment when possible.
Multiple Myeloma: Regulatory Aspects of Treatment Development and Approval
Beth M. Faiman, PhD, CNP, Cleveland Clinic
A focused discussion on the regulatory aspects of drug testing and approval, globally, with respect to the setting of multiple myeloma management.
Educating Patients on Treatment Options for Multiple Myeloma
Beth M. Faiman, PhD, CNP, Cleveland Clinic
Expert panelists consider best methods in educating patients on their options for therapy following a diagnosis of multiple myeloma.
Treatment for Newly Diagnosed Multiple Myeloma: Addressing Disparities in Care
Beth M. Faiman, PhD, CNP, Cleveland Clinic
Comprehensive insight to disparities that may impact a patient’s access to therapy for multiple myeloma and how these may be overcome.
Treatment Considerations for Patients with Newly Diagnosed Multiple Myeloma
Beth M. Faiman, PhD, CNP, Cleveland Clinic
Panelists share a brief discussion on the current treatment armamentarium available to patients with newly diagnosed multiple myeloma.
Role of Diagnostic Testing in Patients with Multiple Myeloma
Beth M. Faiman, PhD, CNP, Cleveland Clinic
Experts in multiple myeloma management consider essential tests that aid in the diagnosis and treatment of newly presenting patients.
Biomarker Analysis Contextualizes RFS Benefit With Nivolumab in Metastatic Melanoma
September 1st 2023Brian Gastman MD, discusses how findings from CheckMate76K contributed to the rationale for a biomarker analysis in that trial’s patient population, key findings from this biomarker analysis, and how these findings may inform further research regarding the benefits of immunotherapy in earlier-stage disease.
Momelotinib Could Represent Pivotal New Treatment Option in Myelofibrosis
Aaron T. Gerds, MD, PhD, expands on the potential role of momelotinib in the treatment of patients with myelofibrosis who present with anemia, details the data from MOMENTUM, and explains what FDA approval of momelotinib could mean for the treatment of this patient population.
Rural Patient Populations at Higher Risk of Lung Cancer Mortality
Logan Roof, MD, discusses the importance of investigating demographic disparities that exist in lung cancer mortality, expands on the results of the population-based CDC database analysis, and discusses potential next steps to address these disparities in the future.
Enfortumab Vedotin Plus Pembrolizumab Sustains Long-Term Benefit in Metastatic Urothelial Carcinoma
Shilpa Gupta, MD, expands on the updated results from EV-103 in patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin, and details the next steps for investigating the combination of enfortumab vedotin plus pembrolizumab in the ongoing phase 3 EV-302 trial.
Educating on Multiple Myeloma: Patient and Physician Resources
Beth M. Faiman, PhD, CNP, Cleveland Clinic
Shared insight from key opinion leaders on educational resources made available to physicians and patients, respectively, regarding multiple myeloma management.
Multiple Myeloma: Challenges in Diagnosis and Role of Multidisciplinary Care
Joseph Mikhael, MD, Translational Genomics Research Institute
Opening its discussion on key unmet needs in multiple myeloma management, a panel of experts discuss key challenges faced when diagnosing patients with multiple myeloma and review the impact of having a multidisciplinary care team.
Dr Gupta on Criteria for the EV-103 Trial in Advanced Urothelial Cancer
July 13th 2023Shilpa Gupta, MD, discusses the enrollment criteria used for the phase 1/2 EV-103 trial in patients with locally advanced or metastatic urothelial carcinoma, and highlights next steps for the investigation of the frontline combination of enfortumab vedotin and pembrolizumab in the phase 3 EV-302 trial.
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
